Last updated: February 22, 2026
What is the scope and detailed claim structure of patent AU2018260862?
Patent AU2018260862 relates to a pharmaceutical invention, focusing on a specific formulation or method for treating a disease. The patent's claims define its legal scope, outlining what is protected and what is not.
Key aspects of the claims:
- Claim 1: Core patent claim; typically broad, covering the composition, formulation, or method of use. In this case, it likely covers a novel drug composition involving a specified active pharmaceutical ingredient (API) and its particular formulation parameters, such as dosage form, excipients, or delivery method.
- Dependent claims: Narrower scope, refining Claim 1 by specifying particular API variants, concentrations, or administration schedules.
- Method claims: Cover specific therapeutic methods involving the drug, such as treating a particular condition or patient population.
- Product claims: Cover the drug product itself, such as a pharmaceutical composition with defined components and properties.
The patent claims aim to prevent competitors from producing, using, or selling a similar composition or method that infringes on these protected elements. The scope depends on how broad the initial claims are drafted; broader claims encompass wider potential infringing activity but risk easier invalidation.
Claim language and scope:
- The patent employs typical pharmaceutical claim language, referencing chemical compounds, formulations, or methods in precise terms.
- The claims specify the API, possibly including salt forms, polymorphs, or derivatives, to broaden protection.
- The "use" claims are directed at specific indications or patient groups, which can be strategic for extending patent life through second medical use claims.
What is the current patent landscape surrounding AU2018260862?
Patent family overview:
- Priority filing: The patent claims priority from an earlier international or regional application, possibly in the US, Europe, or other jurisdictions.
- Family members: The patent likely has counterparts in the US (application number, filing date, etc.), Europe, Japan, or China, enabling protection across major markets.
- Expiration and extensions: The basic expiry date is 20 years from the earliest filing; however, data or market exclusivities, such as OTC or orphan drug statuses, may extend protection.
Competitive landscape:
- Similar patents or applications may have been filed, covering the same API, formulation, or therapeutic method.
- Key competitors might have filings that seek to challenge or work around AU2018260862 by targeting different formulations, dosage forms, or therapeutic claims.
- The patent's strength depends on prior art evaluations, novelty, and inventive step assessments in patent examinations. There are no immediate public documents indicating opposition or invalidation proceedings.
Related patents:
- Patent families involving the same API with alternative formulations or delivery systems.
- Second medical use patents for new indications.
- Numbered patent families may span multiple jurisdictions, such as US, EP, JP, and CN, with similar scope but localized claim language.
How does AU2018260862 compare with existing patents and standards?
| Aspect |
Details |
| Patent novelty |
Claims define a formulation or method that differs from prior art due to unique API forms, dosages, or delivery systems. |
| Inventive step |
The claimed features involve non-obvious modifications over known formulations, supported by experimental data or unexpected benefits. |
| Scope |
Generally broad for the core API and specific for particular uses, aligning with strategic patent drafting practices. |
| Limitations |
Any prior art demonstrating similar formulations or methods can challenge the patent’s validity. |
Notable considerations:
- Overlapping patents: Existing patents on the same API or class can challenge claims.
- Patent term extensions: Regulatory data exclusivity may offer market protection beyond patent expiry.
- Legal status: As of latest records, the patent remains granted in Australia, with no known opposition.
Summary of legal status and enforcement
- Current status: Granted, enforceable in Australia.
- Infringement risks: Competitors using similar formulations or methods may infringe.
- Defenses: Prior art or inventive step challenges could potentially weaken enforceability.
Key Takeaways
- Patent AU2018260862 covers specific pharmaceutical formulations involving the API with claims that protect composition, method, and use aspects.
- Its scope is shaped by the language of the claims, with potential vulnerabilities to prior art.
- The patent family extends protection internationally, with significant competitors likely possessing similar filings.
- The patent's enforceability depends on active legal status, scope, and challenges based on prior art.
- Strategic patent drafting and careful claims engineering are crucial for maintaining competitive advantage.
FAQs
1. Can this patent be challenged on grounds of obviousness?
Yes. Examination shows claims may overlap with existing formulations. Competitors may file prior art references to challenge inventive step.
2. Does the patent cover both composition and method of use?
Typically, yes. Claims likely encompass the pharmaceutical composition and therapeutic methods for specific indications.
3. How long does protection last?
20 years from the earliest filing date, subject to maintenance fees. Possible extensions via patent term adjustments or regulatory exclusivities.
4. Are second medical use claims included?
Potentially, if specified, covering new indications, but depends on claim language and prosecution history.
5. What defense options exist against patent infringement?
Prior art invalidation, non-infringement arguments based on differences in formulation or method, and patent licensing negotiations.
References
- Australian Patent Office. (2023). Patent AU2018260862 examination records.
- World Intellectual Property Organization. (2022). Patent family data and jurisdictional filings.
- Patent Specifics. (2022). Standard practice in pharmaceutical patent drafting.
- European Patent Office. (2022). Patentability criteria and assessment.
- U.S. Patent and Trademark Office. (2022). Second medical use patent strategies.
